Altimmune (ALT) a name moving strong the last two weeks seeing 1500 Dec. $10 calls bought this morning $2.35 offers, Phase 1b NAFLD data in Q3 and interim Phase 2b obesity in Q4 seen setting the stage for potential partnerships